FDA Gives Guidance on Manufacturing During COVID-19

News
Article

The temporary guidance discusses the resumption of normal manufacturing during the COVID-19 pandemic.

On September 11, 2020, FDA published guidance to help manufacturers of drugs and biologics transition their manufacturing operations impacted by the COVID-19 pandemic back to “normal”. In the guidance, the agency provides recommendations for prioritizing products as normal operations resume and for remediation of current good manufacturing practice (CGMP) activities impacted by the pandemic.

During the pandemic, manufacturing operations may have been impacted by employee illness, travel restrictions, plant closures, and disruptions to the supply chain. The guidance provides detailed information for addressing CGMP deviations, developing a plan to resume normal manufacturing activities, and prioritizing activities. The document includes a list of examples where remediation may be necessary.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes